Cargando…

Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden

The pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides is complex; however, a better understanding in recent years has enabled new therapeutic approaches. In recent years priority was given to the minimization of treatment-associated toxicity. For induction of remiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Schönermarck, Ulf, Vielhauer, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404175/
https://www.ncbi.nlm.nih.gov/pubmed/34484454
http://dx.doi.org/10.1007/s11560-021-00527-w
_version_ 1783746117347835904
author Schönermarck, Ulf
Vielhauer, Volker
author_facet Schönermarck, Ulf
Vielhauer, Volker
author_sort Schönermarck, Ulf
collection PubMed
description The pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides is complex; however, a better understanding in recent years has enabled new therapeutic approaches. In recent years priority was given to the minimization of treatment-associated toxicity. For induction of remission of severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), glucocorticoids are used as well as cyclophosphamide and rituximab. The current recommendations enable a more rapid tapering of steroid dose and advise caution in the use of plasmapheresis. Rituximab and azathioprine are available options for maintenance of remission. The choice of medication and duration of remission maintenance are oriented particularly to the risk of recurrence. The importance of low-dose steroids has not yet been finally clarified. New treatment approaches, such as the C5a receptor inhibitor avacopan could enable a minimized steroid treatment in the future. The treatment of eosinophilic granulomatosis with polyangiitis (EGPA) is less evidence-based and consists of glucocorticoids, immunosuppressive agents depending on the severity and increasingly more biologics, e.g. interleukin‑5 blockade. Supportive measures (e.g. vaccinations, infection prophylaxis, cardiovascular risk management) are increasing in importance. Future treatment strategies must take the individual risk (e.g. ANCA subtype, relapse risk) more into consideration for selection and duration of treatment.
format Online
Article
Text
id pubmed-8404175
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-84041752021-08-30 Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden Schönermarck, Ulf Vielhauer, Volker Nephrologe Leitthema The pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides is complex; however, a better understanding in recent years has enabled new therapeutic approaches. In recent years priority was given to the minimization of treatment-associated toxicity. For induction of remission of severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), glucocorticoids are used as well as cyclophosphamide and rituximab. The current recommendations enable a more rapid tapering of steroid dose and advise caution in the use of plasmapheresis. Rituximab and azathioprine are available options for maintenance of remission. The choice of medication and duration of remission maintenance are oriented particularly to the risk of recurrence. The importance of low-dose steroids has not yet been finally clarified. New treatment approaches, such as the C5a receptor inhibitor avacopan could enable a minimized steroid treatment in the future. The treatment of eosinophilic granulomatosis with polyangiitis (EGPA) is less evidence-based and consists of glucocorticoids, immunosuppressive agents depending on the severity and increasingly more biologics, e.g. interleukin‑5 blockade. Supportive measures (e.g. vaccinations, infection prophylaxis, cardiovascular risk management) are increasing in importance. Future treatment strategies must take the individual risk (e.g. ANCA subtype, relapse risk) more into consideration for selection and duration of treatment. Springer Medizin 2021-08-30 2021 /pmc/articles/PMC8404175/ /pubmed/34484454 http://dx.doi.org/10.1007/s11560-021-00527-w Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Leitthema
Schönermarck, Ulf
Vielhauer, Volker
Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden
title Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden
title_full Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden
title_fullStr Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden
title_full_unstemmed Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden
title_short Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden
title_sort strategien zur effektiven und nebenwirkungsarmen therapie anca-assoziierter vaskulitiden
topic Leitthema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404175/
https://www.ncbi.nlm.nih.gov/pubmed/34484454
http://dx.doi.org/10.1007/s11560-021-00527-w
work_keys_str_mv AT schonermarckulf strategienzureffektivenundnebenwirkungsarmentherapieancaassoziiertervaskulitiden
AT vielhauervolker strategienzureffektivenundnebenwirkungsarmentherapieancaassoziiertervaskulitiden